Bekos, C.; Muqaku, B.; Dekan, S.; Horvat, R.; Polterauer, S.; Gerner, C.; Aust, S.; Pils, D.
NECTIN4 (PVRL4) as Putative Therapeutic Target for a Specific Subtype of High Grade Serous Ovarian Cancer—An Integrative Multi-Omics Approach. Cancers 2019, 11, 698.
https://doi.org/10.3390/cancers11050698
AMA Style
Bekos C, Muqaku B, Dekan S, Horvat R, Polterauer S, Gerner C, Aust S, Pils D.
NECTIN4 (PVRL4) as Putative Therapeutic Target for a Specific Subtype of High Grade Serous Ovarian Cancer—An Integrative Multi-Omics Approach. Cancers. 2019; 11(5):698.
https://doi.org/10.3390/cancers11050698
Chicago/Turabian Style
Bekos, Christine, Besnik Muqaku, Sabine Dekan, Reinhard Horvat, Stephan Polterauer, Christopher Gerner, Stefanie Aust, and Dietmar Pils.
2019. "NECTIN4 (PVRL4) as Putative Therapeutic Target for a Specific Subtype of High Grade Serous Ovarian Cancer—An Integrative Multi-Omics Approach" Cancers 11, no. 5: 698.
https://doi.org/10.3390/cancers11050698
APA Style
Bekos, C., Muqaku, B., Dekan, S., Horvat, R., Polterauer, S., Gerner, C., Aust, S., & Pils, D.
(2019). NECTIN4 (PVRL4) as Putative Therapeutic Target for a Specific Subtype of High Grade Serous Ovarian Cancer—An Integrative Multi-Omics Approach. Cancers, 11(5), 698.
https://doi.org/10.3390/cancers11050698